RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients

Sima Kalantari; Bahram Kazemi; Raheleh Roudi; Hakimeh Zali; Alberto D'Angelo; Ashraf Mohamadkhani; Zahra Madjd; Akram Pourshams

doi:10.1002/cbin.11924

RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients

Sima Kalantari, Bahram Kazemi, Raheleh Roudi, Hakimeh Zali, Alberto D'Angelo, Ashraf Mohamadkhani, Zahra Madjd, Akram Pourshams

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (SciVal)

Abstract

We investigated the transcriptional profile of whole blood in early and metastatic stages of pancreatic cancer (PaC) patients to identify potential diagnostic factors for early diagnosis. Blood samples from 18 participants (6 healthy individuals, 6 patients in early stage (I/II) PaC, and 6 patients in metastatic PaC) were analyzed by RNA-sequencing. The expression levels of identified genes were subsequently compared with their expression in pancreatic tumor tissues based on TCGA data reported in UALCAN and GEPIA2 databases. Overall, 331 and 724 genes were identified as differentially expressed genes in early and metastatic stages, respectively. Of these, 146 genes were shared by early and metastatic stages. Upregulation of PTCD3 and UBA52 genes and downregulation of A2M and ARID1B genes in PaC patients were observed from early stage to metastasis. TCGA database showed increasing trend in expression levels of these genes from stage I to IV in pancreatic tumor tissue. Finally, we found that low expression of PTCD3, A2M, and ARID1B genes and high expression of UBA52 gene were positively correlated with PaC patients survival. We identified a four-gene set (PTCD3, UBA52, A2M, and ARID1B) expressed in peripheral blood of early stage and metastatic PaC patients that may be useful for PaC early diagnosis.

Original language	English
Pages (from-to)	238-249
Number of pages	12
Journal	Cell Biology International
Volume	47
Issue number	1
Early online date	13 Oct 2022
DOIs	https://doi.org/10.1002/cbin.11924
Publication status	Published - 31 Jan 2023

Bibliographical note

Funding Information:
We thank all the patients and healthy donors who participated in the present study. We are grateful to Dr. Mojgan Bandehpour for RNA isolation procedure consulting, Beijing Genomics Institute (BGI.Group) for RNA‐sequencing, Dr. Babak Arefnejad for RNA‐sequencing analysis, and all those who helped in this project. This project was funded by the National Institute for Medical Research Development (grant number: 982950, grant recipient: Akram Pourshams).

Keywords

blood profiling
early stage
metastasis
pancreatic cancer
RNA-sequencing

ASJC Scopus subject areas

Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cbin.11924

Cite this

@article{2f3863e58cf74ebc840f8a6f00cfbefe,

title = "RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients",

abstract = "We investigated the transcriptional profile of whole blood in early and metastatic stages of pancreatic cancer (PaC) patients to identify potential diagnostic factors for early diagnosis. Blood samples from 18 participants (6 healthy individuals, 6 patients in early stage (I/II) PaC, and 6 patients in metastatic PaC) were analyzed by RNA-sequencing. The expression levels of identified genes were subsequently compared with their expression in pancreatic tumor tissues based on TCGA data reported in UALCAN and GEPIA2 databases. Overall, 331 and 724 genes were identified as differentially expressed genes in early and metastatic stages, respectively. Of these, 146 genes were shared by early and metastatic stages. Upregulation of PTCD3 and UBA52 genes and downregulation of A2M and ARID1B genes in PaC patients were observed from early stage to metastasis. TCGA database showed increasing trend in expression levels of these genes from stage I to IV in pancreatic tumor tissue. Finally, we found that low expression of PTCD3, A2M, and ARID1B genes and high expression of UBA52 gene were positively correlated with PaC patients survival. We identified a four-gene set (PTCD3, UBA52, A2M, and ARID1B) expressed in peripheral blood of early stage and metastatic PaC patients that may be useful for PaC early diagnosis.",

keywords = "blood profiling, early stage, metastasis, pancreatic cancer, RNA-sequencing",

author = "Sima Kalantari and Bahram Kazemi and Raheleh Roudi and Hakimeh Zali and Alberto D'Angelo and Ashraf Mohamadkhani and Zahra Madjd and Akram Pourshams",

note = "Funding Information: We thank all the patients and healthy donors who participated in the present study. We are grateful to Dr. Mojgan Bandehpour for RNA isolation procedure consulting, Beijing Genomics Institute (BGI.Group) for RNA‐sequencing, Dr. Babak Arefnejad for RNA‐sequencing analysis, and all those who helped in this project. This project was funded by the National Institute for Medical Research Development (grant number: 982950, grant recipient: Akram Pourshams). ",

year = "2023",

month = jan,

day = "31",

doi = "10.1002/cbin.11924",

language = "English",

volume = "47",

pages = "238--249",

journal = "Cell Biology International",

issn = "1065-6995",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients

AU - Kalantari, Sima

AU - Kazemi, Bahram

AU - Roudi, Raheleh

AU - Zali, Hakimeh

AU - D'Angelo, Alberto

AU - Mohamadkhani, Ashraf

AU - Madjd, Zahra

AU - Pourshams, Akram

N1 - Funding Information: We thank all the patients and healthy donors who participated in the present study. We are grateful to Dr. Mojgan Bandehpour for RNA isolation procedure consulting, Beijing Genomics Institute (BGI.Group) for RNA‐sequencing, Dr. Babak Arefnejad for RNA‐sequencing analysis, and all those who helped in this project. This project was funded by the National Institute for Medical Research Development (grant number: 982950, grant recipient: Akram Pourshams).

PY - 2023/1/31

Y1 - 2023/1/31

N2 - We investigated the transcriptional profile of whole blood in early and metastatic stages of pancreatic cancer (PaC) patients to identify potential diagnostic factors for early diagnosis. Blood samples from 18 participants (6 healthy individuals, 6 patients in early stage (I/II) PaC, and 6 patients in metastatic PaC) were analyzed by RNA-sequencing. The expression levels of identified genes were subsequently compared with their expression in pancreatic tumor tissues based on TCGA data reported in UALCAN and GEPIA2 databases. Overall, 331 and 724 genes were identified as differentially expressed genes in early and metastatic stages, respectively. Of these, 146 genes were shared by early and metastatic stages. Upregulation of PTCD3 and UBA52 genes and downregulation of A2M and ARID1B genes in PaC patients were observed from early stage to metastasis. TCGA database showed increasing trend in expression levels of these genes from stage I to IV in pancreatic tumor tissue. Finally, we found that low expression of PTCD3, A2M, and ARID1B genes and high expression of UBA52 gene were positively correlated with PaC patients survival. We identified a four-gene set (PTCD3, UBA52, A2M, and ARID1B) expressed in peripheral blood of early stage and metastatic PaC patients that may be useful for PaC early diagnosis.

AB - We investigated the transcriptional profile of whole blood in early and metastatic stages of pancreatic cancer (PaC) patients to identify potential diagnostic factors for early diagnosis. Blood samples from 18 participants (6 healthy individuals, 6 patients in early stage (I/II) PaC, and 6 patients in metastatic PaC) were analyzed by RNA-sequencing. The expression levels of identified genes were subsequently compared with their expression in pancreatic tumor tissues based on TCGA data reported in UALCAN and GEPIA2 databases. Overall, 331 and 724 genes were identified as differentially expressed genes in early and metastatic stages, respectively. Of these, 146 genes were shared by early and metastatic stages. Upregulation of PTCD3 and UBA52 genes and downregulation of A2M and ARID1B genes in PaC patients were observed from early stage to metastasis. TCGA database showed increasing trend in expression levels of these genes from stage I to IV in pancreatic tumor tissue. Finally, we found that low expression of PTCD3, A2M, and ARID1B genes and high expression of UBA52 gene were positively correlated with PaC patients survival. We identified a four-gene set (PTCD3, UBA52, A2M, and ARID1B) expressed in peripheral blood of early stage and metastatic PaC patients that may be useful for PaC early diagnosis.

KW - blood profiling

KW - early stage

KW - metastasis

KW - pancreatic cancer

KW - RNA-sequencing

UR - http://www.scopus.com/inward/record.url?scp=85139756434&partnerID=8YFLogxK

U2 - 10.1002/cbin.11924

DO - 10.1002/cbin.11924

M3 - Article

AN - SCOPUS:85139756434

SN - 1065-6995

VL - 47

SP - 238

EP - 249

JO - Cell Biology International

JF - Cell Biology International

IS - 1

ER -

RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this